Colorectal cancer screening program in the Czech Republic – 2021 quality indicators evaluation

Czech version

Authors: Chloupková R. ^1,2; Ngo O. ^1,2; Štěpán Suchánek ^3,4; Miroslav Zavoral ^3,4; Martykánová L. ^1,2; Hejduk K. ^1,2; Májek O. ^1,2
Authors‘ workplace: ÚZIS ČR, Národní screeningové centrum, Praha ¹; Institut bio statistiky a analýz, LF MU, Brno ²; Interní klinika 1. LF UK a ÚVN, Praha ³; Ústav gastrointestinální onkologie ÚVN, Praha ⁴
Published in: Gastroent Hepatol 2022; 76(5): 379-385
Category: Gastrointestinal Oncology: Original Article
doi: https://doi.org/10.48095/ccgh2022379

Overview

Background: Compared to other European countries, the Czech Republic has long been one of the countries with high rates of incidence and mortality of colorectal cancer. The screening program was implemented in 2000 and has become an essential part of prevention policy in the Czech Republic. Continuous monitoring of the entire screening process is necessary to ensure high quality and the resulting success of the program. The aim of the paper is to present the current results of the National Colorectal Cancer Screening Program using selected indicators in accordance with established recommendations. Material and Methods: The analysis was performed on data on preventive colonoscopies performed in Centers for screening colonoscopy (Centers) in 2021, with selected performance indicators being evaluated (number of preventive colonoscopies, adequate bowel preparation, caecal intubation rate and adenoma detection rate). The resulting performance indicators were evaluated by the published recommendations of the Czech Gastroenterological Society to point to the results of the program as a whole, not to assess individual Centers. Results: The majority (94.7%) of the Centers achieved the basic performance indicator (number of preventive colonoscopies). The performance indicator of adequate bowel preparation was met by 83.6% of Centers (the average proportion of colonoscopies with adequate bowel preparation in the Czech Republic is 93.8%). The optimal proportion of caecal intubation (90.0%) was reached by 87.2% of Centers in 2021. Only 16 Centers (8.5%) did not meet the adenoma detection rate indicator, but a high variability was observed across the Centers (11.6% to 68.2%) – a similar situation was observed in evaluation by gender and indication. A relatively low adenoma detection rate in follow-up colonoscopies after positive FOBT could be related to high and variable FOBT, which may indicate redundant colonoscopies and overburden the Centers. Conclusion: Some Centers do not reach the reference values for performance indicators according to reference values. It is necessary to continue monitoring performance indicators at the level of individual Centers to improve the quality of the entire program.

Keywords:

screening – colonoscopy – colorectal cancer – performance indicators

Sources

1. Ferlay J, Ervik M, Lam F et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2020 [online]. Dostupné z: https: //gco.iarc.fr/today/home.

2. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. 2022 [online]. Dostupné z: http: //www.svod.cz.

3. Kim PJ, Plescia J, Clevers H et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003; 362 (9379): 205–209. doi: 10.1016/S0140-6736 (03) 13910-4.

4. Wild C, Stewart BW, World Health Organization, International Agency for Research on Cancer. World Cancer Report 2014. Lyon: International Agency for Research on Cancer 2014.

5. European Council. Council Recommendation of 2 December 2003 on cancer screening. 2003 [online]. Dostupné z: http: //eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ: L: 2003: 327: 0034: 0038: EN: PDF.

6. Vyhláška č. 259/2020 Sb., vyhláška, kterou se mění vyhláška č. 134/1998 Sb., kterou se vydává seznam zdravotních výkonů s bodovými hodnotami, ve znění pozdějších předpisů, a vyhláška č. 70/2012 Sb., o preventivních prohlídkách, ve znění vyhlášky č. 317/2016 Sb. – znění od 1. 7. 2020. In: Zákony pro lidi.cz. 2022 [online]. Dostupné z: https: //www.zakonyprolidi.cz/cs/2020-259#f6814436.

7. Seznam zdravotních výkonů 2.0.0.184. Praha: Ministerstvo zdravotnictví České republiky. 2016 [online]. Dostupné z: https: //szv.mzcr.cz/.

8. Zavoral M, Vojtěchová G, Májek O et al. Populační screening kolorektálního karcinomu v České republice. Cas Lek Cesk 2016; 155 (1): 7–12.

9. Dušek L, Májek O, Blaha M et al. Koncepce populačního screeningu v České republice, metodika a první výsledky adresného zvaní občanů do preventivních onkologických programů. Klin Onkol 2014; 27 (Suppl 2): 59–68.

10. Segnan N, Patnick J, von Karsa L. European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis – First Edition. Luxembourg: Publications Office ot the European Union 2010.

11. Falt P, Urban O, Suchánek Š et al. Doporučené postupy České gastroenterologické společnosti ČLS JEP pro diagnostickou a terapeutickou koloskopii. Gastroenterol Hepatol 2016; 70 (6): 523–538. doi: 10.14735/amgh2016csgh.info19.

12. IBM Corp. Released 2021. IBM SPSS Statistics for Windows, Version 28.0. Armonk, NY: IBM Corp.

13. Hassan C, East J, Radealli F et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2019. Endoscopy 2019; 51 (8): 775–794. doi: 10.1055/a-0959-0505.

14. Seifert B, Král N, Suchánek Š et al. Čas pro změny ve screeningu kolorektálního karcinomu v ČR. Acta medicinae. Praha: ERA Média s. r. o. 2018; 6 (12): 62–66.